Home | Welcome to Contract Pharma   
Last Updated Friday, May 22 2015


Tigermed Gains Majority Stake in Frontage

Published August 5, 2014
Hangzhou Tigermed Consulting Co., Ltd. and Frontage Laboratories, Inc. have completed an investment agreement, following approval by the China Securities and Regulatory Commission, under which Tigermed has acquired a majority stake in Frontage, a provider of bioanalysis, preclinical studies, early phase clinical studies and product development services for biopharma companies. Tigermed provides outsourced clinical development services across China and Asia Pacific regions.
Frontage will continue to operate independently, and will retain its name, management team and operations facilities.
“Our strategic partnership with Frontage firmly establishes our global clinical trial network,” said Dr. Xiaoping Ye, founder and chief executive officer of Tigermed. “The two companies share similar philosophies and operational approaches, which combined with additional complementary strengths in research integrity and reliability will now benefit clients on a much larger scale.”
“Joining efforts with Tigermed allows us to expand our geographic range and align our early development services with Tigermed’s late phase clinical operations for a scope that will serve clients looking for full-service, high quality, global drug development resources,” said Song Li, founder and chief executive officer of Frontage.

blog comments powered by Disqus

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On